Tumor Rebiopsy - Guide to Targeted Therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F16%3A10331862" target="_blank" >RIV/00669806:_____/16:10331862 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/16:10331862

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Tumor Rebiopsy - Guide to Targeted Therapy

Popis výsledku v původním jazyce

In the last decade there has been significant progress in the new treatment options for NSCLC (non small cell lung cancer). However, resistence arises in all therapeutic modalities (chemotherapy, targeted / biological therapy, immunotherapy) for advanced lung cancer after certain time. This issue is widely debated in the context of targeted therapy - e.g. epidermal grow factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Our article shows a case report of a patient with changing EGFR status. There was a change notified between a primary resected tumor and tumor recurrence. In addition, remarkable efficacy of EGFR-TKI (erlotinib) in the presence of EGFR mutation T790M is documented. These findings have been briefly discussed with published literal facts. In this context, the future of our patient should focus on efficacy of 3rd generation of EGFR- TKIs and the ability to monitor the development of cancer genome by using so called liquid biopsy.

Název v anglickém jazyce

Tumor Rebiopsy - Guide to Targeted Therapy

Popis výsledku anglicky

In the last decade there has been significant progress in the new treatment options for NSCLC (non small cell lung cancer). However, resistence arises in all therapeutic modalities (chemotherapy, targeted / biological therapy, immunotherapy) for advanced lung cancer after certain time. This issue is widely debated in the context of targeted therapy - e.g. epidermal grow factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Our article shows a case report of a patient with changing EGFR status. There was a change notified between a primary resected tumor and tumor recurrence. In addition, remarkable efficacy of EGFR-TKI (erlotinib) in the presence of EGFR mutation T790M is documented. These findings have been briefly discussed with published literal facts. In this context, the future of our patient should focus on efficacy of 3rd generation of EGFR- TKIs and the ability to monitor the development of cancer genome by using so called liquid biopsy.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FC - Pneumologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Surgery-Acta Chirurgica Austriaca

ISSN

1682-8631

e-ISSN

—

Svazek periodika

48

Číslo periodika v rámci svazku

Suppl. 3

Stát vydavatele periodika

AT - Rakouská republika

Počet stran výsledku

3

Strana od-do

194-196

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—